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Adverse effects of inhaled corticosteroids Not serious if care is taken
An inhaled corticosteroid is now the main agent used for prophylaxis in adult asthma and increasingly so in children. Administration oflarge doses ofinhaled corticosteroids, aided by more concentrated aerosol preparations and improved delivery devices, has allowed further reductions in the use of oral corticosteroids. So it has to be asked what is the balance of advantages and disadvantages of these agents. Inhaled corticosteroids are usually well tolerated. Thrush occurs in 5-13% of adults'3 and 1% of children4; the frequency relates to the dose2 and its frequency3 and may be reduced with spacer devices.5 Dysphonia due to a reversible vocal cord deformity, resulting from laryngeal myopathy, is less common.6 Treatment rarely has to be stopped because of thrush, and dysphonia may not recur if lower doses are tried. Posterior subcapsular cataracts have now been reported in one child7 and three adults8 taking inhaled beclomethasone dipropionate for two to 12 years with occasional short courses of oral corticosteroids and were attributed to the inhaled corticosteroid.
In adults suppression of the adrenal glands from systemic absorption may occur with a dose of beclomethasone dipropionate above 1500 [ig daily.910 In children dose dependent suppression of the adrenal glands has been reported with doses as low as 400 [tg daily," which has led to concern about their effect on growth. Asthma may itself stunt growth, although in a cross sectional study reduced stature was found to be as common in children with rhinitis alone.'2 No effect on growth was seen over three to five years in 19 asthmatic children taking doses of around 400 [tg of beclomethasone dipropionate daily. 'I A recent cross sectional study compared the growth of 81 asthmatic children having doses of 200-800 Fg of beclomethasone dipropionate daily (mean 15 rig/kg body weight) with that of 249 asthmatic children receiving other treatment, finding that height was half a standard deviation less in those treated with beclomethasone dipropionate.'4 Although this suggests that beclomethasone dipropionate may retard growth, other explanations are possible. Those having beclomethasone dipropionate were older and may have had more severe disease; alternatively, asthma itself may well delay puberty, thus causing the small growth impairment seen in the older, beclomethasone treated children.'5 Delay in puberty occurred in 30 patients in a longitudinal study of 66 asthmatic children followed for a mean of 13-1 years but final heights were judged to be normal. '6 In 26 children receiving up to 600 [tg beclomethasone dipropionate daily for a mean of 5 8 years growth in height was apparently inhibited by delayed puberty in 11, but they later regained their predicted height.'6 The possibility remains then that inhaled corticosteroids may stunt growth, but with standard paediatric doses it is unlikely to become a clinical problem.
Metabolic studies in healthy adults taking 500 [tg of beclomethasone dipropionate twice daily, a dose not usually associated with adrenal suppression, have shown decreased insulin sensitivity and small but significant rises in both total and high density lipoprotein cholesterol concentrations. 1 ' The importance of these changes is uncertain, although even small increases in plasma cholesterol concentrations within the accepted normal range are thought to increase the risk of cardiovascular disease. 18 There is also some evidence to suggest that inhaled corticosteroids cause osteoporosis: doses of 400-800 tg daily may reduce the total body calcium to values similar to those found in postmenopausal patients with crush fractures. '" Inhaled corticosteroids are an integral part of the management of asthma. Nevertheless, dosage requires titration, with increasing doses being prescribed for continuing symptoms, low mean peak expiratory flow values, or unacceptable diurnal variations of peak flow. Towards the end of the therapeutic dosage range few adverse effects in the short or long term are expected but the doctor should be aware of the metabolic effects of higher doses that are insufficient to cause BMJ VOLUME 298adrenal suppression. Caution and close observation are required when prescribing inhaled corticosteroids in children. Nevertheless, they remain a major therapeutic advance in management with few serious side effects compared with long term daily oral corticosteroids.
In 1983 the first genetic marker for Huntington's disease was found.' The discovery not only provided the impetus for advances in many other genetic disorders but also posed important ethical questions about using these markers in predicting a serious and untreatable neurological disease. Five years later how have our thoughts progressed, and how has the work affected the prospects for families with a history of Huntington's disease?
The first point to be emphasised is that the findings have been confirmed widely in Britain2 and elsewhere.3 Undoubtedly Huntington's disease is determined by a single genetic locus, an important theoretical and practical point, particularly given that in some other disorders (such as polycystic kidney disease and osteogenesis imperfecta) more than one locus is concerned. Numerous further markers have been studied since the G8 linkage was recognised, several of which are closer to the gene for Huntington's disease than G8.4-6 Together these markers form a framework for constructing a genetic map of the region of chromosome 4 that contains the gene for Huntington's disease. Physical mapping techniques have also contributed to this map: cell lines derived from patients with Wolf-Hirschhorn syndrome show a variable loss of material from chromosome 4 in this region and can be used to order markers,7 and pulsed field gel electrophoresis permits the separation and ordering of large DNA fragments in the region. A new approach is radiation mapping, which uses the fragmentation of chromosomes exposed to radiation to order gene markers. 8 This work has shown that the gene for Huntington's disease is located at the tip of the short arm of chromosome 4, with all the known markers proximal to it and very little DNA between it and the end of the chromosome. Nevertheless, the gene itself has not been identified.
The principal practical consequence from these advances is that predictive testing for Huntington's disease is now a reality, though because of the ethical issues9 '°clinical applications have been cautious and confined to a few special centres. The initial form of prediction was "exclusion testing" in pregnancy to determine whether a parent had passed on to the fetus either the "at risk" marker type or the type received from the unaffected side of the family." Such testing has the advantage that the parent's own risk is unaltered, whatever the result, but the disadvantage that if Huntington's disease is not excluded the risk for the fetus is raised to 50%, the parent's own risk. None the less, an appreciable number of couples have found this approach acceptable.
Presymptomatic testing for the gene is now under way in several centres in Britain, Canada, and the United States.'2 Given the necessary family structure most subjects can now be given test results that will increase their risk to around 95% or lower it to around 5%. Unfortunately, most individuals do not have the necessary affected relatives in previous generations alive to permit such a definitive prediction, and this, rather than deficiencies in the markers, is the main limitation of predictive testing.'3 The need for DNA isolation and banking of samples from key family members remains as great as when the topic was first discussed five years ago. 14 No centre should embark on this testing without the most careful consideration of the pitfalls. Foremost is the need for adequate support: not only is the laboratory analysis time consuming but so also are the counselling before the test and the family documentation, which require a multidisciplinary team. A considerable number of people requesting prediction are clinically affected when first seen,'5 a difficult problem for the counsellors, and a further issue is that of prediction for children (notably those for adoption), which we consider cannot be justified at present. '6 It will be some time before we have adequate information on the outcome of testing-in particular its acceptability and the long term effects on those concerned. Until then the topic is bound to remain controversial, and investigators have a duty to document their activities in detail and to ensure that these are carried out to the highest standards. Once the Huntington's disease gene itself is isolated and its product identified, it will be possible to think in terms of modifying the course of the disorder. When this can be achieved it may
